Arrow Therapeutics Overview
- Year Founded
-
1998
- Status
-
Acquired/Merged
- Employees
-
58
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$150M
Arrow Therapeutics General Information
Description
Developer of anti-viral drugs and therapies. The company focuses on developing anti-infective drugs which includes novel antibiotics, antivirals and antifungals for conditions such as hepatitis C, providing healthcare professionals with drugs for viral diseases.
Contact Information
Website
www.arrowtherapeutics.comCorporate Office
- 7 Trinity Street
- London SE1 1DB
- England, United Kingdom
Corporate Office
- 7 Trinity Street
- London SE1 1DB
- England, United Kingdom
Arrow Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Merger/Acquisition | 01-Feb-2007 | $150M | Completed | Generating Revenue | ||
| 4. Later Stage VC | 02-May-2006 | Completed | Generating Revenue | |||
| 3. Early Stage VC (Series B) | 01-Dec-2003 | Completed | Generating Revenue | |||
| 2. Early Stage VC | 06-Jul-2000 | $16.8M | $18.4M | Completed | Product Development | |
| 1. Seed Round | 01-Jan-1999 | $1.67M | $1.67M | Completed | Startup |
Arrow Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| B2 Preferred |
Arrow Therapeutics Patents
Arrow Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2011151651-A1 | Benzodiazepine compounds useful for the treatment of hepatitis c | Inactive | 03-Jun-2010 | ||
| WO-2011151652-A1 | Benzodiazepine compounds useful for the treatment of hepatitis c | Inactive | 03-Jun-2010 | ||
| WO-2011027156-A1 | Benzodiazepine derivatives for treating hepatitis c infection | Inactive | 03-Sep-2009 | ||
| US-20110059043-A1 | Chemical compounds | Inactive | 03-Sep-2009 | ||
| WO-2010103306-A1 | Benzimidazole derivatives and their use as antivaral agents | Inactive | 10-Mar-2009 | C07D403/06 |
Arrow Therapeutics Signals
Arrow Therapeutics Former Investors (13)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| 3i Group | PE/Buyout | Minority | ||
| Alta Partners | Venture Capital | Minority | ||
| Atlas Venture | Venture Capital | Minority | ||
| Gimv | PE/Buyout | Minority | ||
| ITX (US) | Corporation | Minority |
Arrow Therapeutics FAQs
-
When was Arrow Therapeutics founded?
Arrow Therapeutics was founded in 1998.
-
Where is Arrow Therapeutics headquartered?
Arrow Therapeutics is headquartered in London, United Kingdom.
-
What is the size of Arrow Therapeutics?
Arrow Therapeutics has 58 total employees.
-
What industry is Arrow Therapeutics in?
Arrow Therapeutics’s primary industry is Drug Discovery.
-
Is Arrow Therapeutics a private or public company?
Arrow Therapeutics is a Private company.
-
What is the current valuation of Arrow Therapeutics?
The current valuation of Arrow Therapeutics is .
-
What is Arrow Therapeutics’s current revenue?
The current revenue for Arrow Therapeutics is .
-
How much funding has Arrow Therapeutics raised over time?
Arrow Therapeutics has raised $73.1M.
-
Who are Arrow Therapeutics’s investors?
3i Group, Alta Partners, Atlas Venture, Gimv, and ITX (US) are 5 of 13 investors who have invested in Arrow Therapeutics.
-
When was Arrow Therapeutics acquired?
Arrow Therapeutics was acquired on 01-Feb-2007.
-
Who acquired Arrow Therapeutics?
Arrow Therapeutics was acquired by AstraZeneca.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process